A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: Effect on quality of Life

Chang Hwan Choi, Sun Young Jo, Hyo Jin Park, Sae Kyung Chang, Jeong Sik Byeon, Seung Jae Myung

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.

Original languageEnglish
Pages (from-to)679-683
Number of pages5
JournalJournal of Clinical Gastroenterology
Volume45
Issue number8
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Irritable Bowel Syndrome
Multicenter Studies
Placebos
Quality of Life
Saccharomyces boulardii
Diarrhea
Probiotics
Insurance Benefits

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Choi, Chang Hwan ; Jo, Sun Young ; Park, Hyo Jin ; Chang, Sae Kyung ; Byeon, Jeong Sik ; Myung, Seung Jae. / A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome : Effect on quality of Life. In: Journal of Clinical Gastroenterology. 2011 ; Vol. 45, No. 8. pp. 679-683.
@article{1f093ff687eb4d0a855fe0e909b4ec99,
title = "A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: Effect on quality of Life",
abstract = "Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4{\%} vs 7.0{\%}; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.",
author = "Choi, {Chang Hwan} and Jo, {Sun Young} and Park, {Hyo Jin} and Chang, {Sae Kyung} and Byeon, {Jeong Sik} and Myung, {Seung Jae}",
year = "2011",
month = "9",
day = "1",
doi = "10.1097/MCG.0b013e318204593e",
language = "English",
volume = "45",
pages = "679--683",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome : Effect on quality of Life. / Choi, Chang Hwan; Jo, Sun Young; Park, Hyo Jin; Chang, Sae Kyung; Byeon, Jeong Sik; Myung, Seung Jae.

In: Journal of Clinical Gastroenterology, Vol. 45, No. 8, 01.09.2011, p. 679-683.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome

T2 - Effect on quality of Life

AU - Choi, Chang Hwan

AU - Jo, Sun Young

AU - Park, Hyo Jin

AU - Chang, Sae Kyung

AU - Byeon, Jeong Sik

AU - Myung, Seung Jae

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.

AB - Background: Probiotics confer health benefits to the host. However, its clinical effect on irritable bowel syndrome (IBS) is controversial. AIMS: This study was aimed to evaluate the effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were randomized either to receive S. boulardii at 2×10 live cells as a daily dose (n=34), or placebo (n=33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the treatment phase. IBS-related symptoms, bowel movement frequency, and stool consistency were recorded on a daily basis and assessed each week. Results: The overall improvement in IBS-QOL was higher in S. boulardii group than placebo (15.4% vs 7.0%; P<0.05). All eight domains of IBS-QOL were significantly improved in S. boulardii group; however, placebo group only showed improvements in dysphoria and health worry. Composite scores for IBS symptoms were significantly reduced in both groups to a similar extent. Bowel frequency and stool consistency did not change in either group. Conclusions: S. boulardii improved IBS-QOL better than placebo but was not superior for individual symptoms in patients with diarrhea-predominant IBS or mixed-type IBS.

UR - http://www.scopus.com/inward/record.url?scp=80052037138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052037138&partnerID=8YFLogxK

U2 - 10.1097/MCG.0b013e318204593e

DO - 10.1097/MCG.0b013e318204593e

M3 - Article

C2 - 21301358

AN - SCOPUS:80052037138

VL - 45

SP - 679

EP - 683

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 8

ER -